Bioprinting and micro/nano-scale AM
📍 Where we are: Part IV · Materials and New Systems — Chapter 10 of 19. After combining materials, we move to the extremes of scale and softness: printing living cells, and printing structures smaller than a hair.
Printing with living cells is like trying to 3D print a sandcastle out of live, fragile, thirsty creatures that must stay alive the whole time. The ink must be gentle enough that the cells survive being squeezed through a nozzle, stiff enough to hold a shape, and the finished object needs plumbing so the cells in the middle can drink and breathe. Printing at the micro-scale is the opposite problem: no living things, but a very small pen that moves very slowly.
What this chapter covers
We review bioprinting by technique (extrusion, jetting, light-based), the bioink trade-offs, the vascularization problem, what has reached patients and its regulatory status, and then micro/nano-scale additive manufacturing, focusing on two-photon polymerization (2PP). Each claim is labelled lab-scale, production, or contested, and the chapter ends with a candid maturity ranking.
Problem
Tissues and organs are not just shapes; they are cells in a precise arrangement, fed by blood vessels. Conventional tissue engineering seeds cells into a scaffold; bioprinting tries to place cells and materials directly. The goal ranges from tissue models for drug testing to implants for repair. Murphy, De Coppi and Atala's perspective separates printed acellular devices, such as orthopaedic devices, surgical tools and maxillofacial implants, which have already been used in patients, from bioprinted living constructs, which face considerable translational challenges: integrating the living device with the patient's vasculature, biocompatible bioinks, and deriving a physiologically relevant number of cells [1]. An earlier, much-cited review set out the same promise and hurdles for printing tissues and organs [2]. At the other end of scale, micro-devices such as optics, microfluidics and micro-mechanical parts need features far finer than any powder bed or filament machine can resolve.
State of the art
Techniques and the bioink trade-off
Biofabrication terminology and its technology classes are laid out in a widely used guide [3]; the bioprinting approaches discussed here are extrusion-based, jetting-based and vat-polymerization-based. Reported viability and capability depend on the technique: laser-assisted printing is nozzle-free and can handle bioink viscosity up to 300 mPa·s while maintaining more than 90% cell viability; digital light processing (DLP) reports 75-95% viability with 2-50 µm resolution but suffers from photoinitiator toxicity and limited light penetration [4]. Cell damage depends on the magnitude and duration of stress; higher stress and longer exposure give poorer viability [4].
The central design tension is a trade-off among printing efficiency, precision and viability. In extrusion, high-viscosity bioinks give stable constructs but often damage cells, and low-viscosity bioinks support viability but may collapse [5]. Mitigations include shear-thinning and granular hydrogel bioinks, sacrificial inks and support baths [6]. Bioink design, including hydrogel engineering for biofabrication, is surveyed in highly cited overviews [7][8]. Standardised bioink characterisation and scaled production remain persistent challenges [6]. Evidence level: lab-scale.
The vascularization problem
Without vessels, cells deeper than a short diffusion distance die. Two milestone lab-scale demonstrations attack this differently.
- SWIFT (sacrificial writing into functional tissue). Skylar-Scott et al. assembled hundreds of thousands of organ building blocks into a living matrix of about 200 million cells per millilitre and wrote perfusable channels into it. Perfused cardiac tissue fused and beat synchronously over 7 days, while tissue grown without channels showed core cell death within 12 hours. The authors also report a limit: contractility was modest, about 1% strain compared with about 20% in adult cardiac tissue [9].
- Light-based vascular topologies. Grigoryan et al. used food-dye photoabsorbers in projection stereolithography to print hydrogels with entangled vascular networks and functional intravascular features such as mixers and bicuspid valves, and tested hydrogel carriers in a rodent model of chronic liver injury [10].
Both show that channels can be made. Neither shows a functioning organ; in the sources we read, contractility of the printed heart tissue stayed far below adult values, and capillary-scale networks and long-term durability were not demonstrated.
Volumetric printing
Volumetric additive manufacturing builds all points of an object at once by illuminating a rotating vial of photosensitive material with an evolving light pattern. Kelly et al. printed features as small as 0.3 mm, including soft structures in a gelatin methacrylate hydrogel [11]. Loterie et al. added low-étendue illumination and camera feedback and made centimetre-scale parts in under 30 seconds with 80 µm positive features, in resins above 10 Pa·s without measurable sedimentation [12]. It is fast and gentle on cells, but still lab-scale.
Clinical and regulatory status
Printing acellular scaffolds and devices is established. Implanting cell-laden bioprinted tissue remains investigational. The best-known case is AuriNovo (3DBio Therapeutics), a patient-specific ear implant printed from the patient's own auricular cells with collagen for microtia, announced in June 2022 as a first-in-human implantation within a Phase 1/2a trial expecting 11 patients [13]. The ClinicalTrials.gov record (NCT04399239, Phase 1/2) now lists the trial as terminated, with the reason given as "company decision, not safety related", actual enrollment of 2 and no results posted [14]; we found no marketing approval. Cell-laden printed constructs, cell-seeded scaffolds and acellular scaffolds fall under different regulatory categories and carry different biological risk, which a recent review traces across the EU, US, China and Australia [15]. Murphy et al. describe the regulatory pathways for printed living tissue as untested [1]. Bioink-focused reviews likewise flag open regulatory questions on safety, standardisation and long-term biocompatibility [16].
Micro and nano-scale: two-photon polymerization
2PP polymerises a resin only at the focus of a femtosecond laser, where two photons are absorbed together, giving features at the sub-micrometre scale. Its limit is throughput: sequential scanning of tiny voxels is slow, which is why parallel-focus approaches are being developed. A 2023 Nature Communications paper used digital holography to run up to 2000 individually programmable laser foci, reaching 90 nm resolution and 2,000,000 voxels per second, and fabricated centimetre-scale metastructures [17]. A 2023 review identifies the shortage of two-photon-polymerizable resins as a bottleneck and surveys photoinitiator and resin formulation [18]. Commercial 2PP printers from several vendors exist and were compared in a 2023 round-robin test [19]. Evidence level: commercial research tool and niche production; high-throughput parallel versions are lab-scale.
Why it is hard
- Conflicting requirements. Printability wants stiff, viscous inks; survival wants gentle, soft ones.
- Scale of vasculature. Printing channels is the first step; tissues also need fine capillary-scale networks and the biology to form and sustain them.
- Cell numbers and maturity. Dense tissue needs very high cell numbers (the SWIFT matrix used about 200 million cells per millilitre), and the printed construct must mature into functional tissue (the cardiac example reached about 1% strain against 20% [9]).
- Regulation. A living product is both a device and a biologic, and process validation at the point of care is unresolved.
- Micro-scale throughput. Resolution and speed trade directly; sequential scanning bounds volume.
Maturity ladder: acellular printed implants are in clinical use, cell-laden constructs are investigational, and perfusable tissues and volumetric printing are lab-scale.
Original diagram by the authors, created with AI assistance.
Open questions
- Can a printed tissue be perfused, matured and shown to function at the scale of a clinically useful graft, not a millimetre-scale demonstrator?
- What quality attributes and release tests should regulators accept for cell-laden printed products?
- Can point-of-care printing be validated with acceptable sterility and quality control?
- Can parallel 2PP scale from centimetre-scale demonstrators to throughput that industry can use, and what material families will it support?
- Do volumetric methods remain accurate in cell-laden, light-scattering resins?
Industry impact
Our honest assessment, based on the sources above (it is a judgement, not a measured score): printed acellular implants and surgical models are in clinical use; cell-laden implants are investigational and the best-known ear trial ended after two participants; perfusable tissue models are a research platform; whole-organ printing is not close. 2PP serves research and niche micro-optics and microfluidics, and the road to volume is parallelisation. Companies selling "bioprinted organs" should be read against this ladder. The step from here to large structures is a different problem, explored next in Large-scale AM and construction.
Why it matters
Bioprinting attracts a great deal of hope and money, and it is exactly the area where the gap between a striking figure and a validated, regulated product is widest. Knowing which rung of the ladder a claim sits on is the main skill.
In the real world
The SWIFT and stereolithography vascular work, tomographic volumetric printing, and the AuriNovo trial are the public landmarks: each demonstrates a capability and each shows where the next barrier lies.
Key terms
- Bioink — a printable material, usually a hydrogel, that contains living cells.
- Extrusion bioprinting — pushing bioink through a nozzle.
- Shear-thinning — becoming less viscous under flow, so the ink flows when pushed and holds shape when still.
- Support bath — a gel in which soft structures are printed and held until set.
- SWIFT — sacrificial writing into functional tissue, a method to print channels into dense cell matrices.
- Volumetric additive manufacturing — solidifying a whole object at once with projected light patterns.
- Two-photon polymerization (2PP) — nanoscale printing by two-photon absorption at a laser focus.
- Voxel — a three-dimensional pixel.
- Acellular scaffold — a printed structure without living cells.
- First-in-human trial — the first clinical test of a product in people.
Where this leads
From micrometres to metres: Large-scale AM and construction looks at what changes when parts get very big.